Indeed, Cetuximab plus Wnt inhibitor LGK-974 as a combination treatment strategy for CHD6-high, Ras/Raf WT CRC PDX studies demonstrated the feasibility (Fig. 8f–h). This evidence concerns the gene CHD6 and colorectal carcinoma.